KR20230084524A - G13d 돌연변이를 갖는 ras에 대한 hla 클래스 ii-제한된 dq t 세포 수용체 - Google Patents

G13d 돌연변이를 갖는 ras에 대한 hla 클래스 ii-제한된 dq t 세포 수용체 Download PDF

Info

Publication number
KR20230084524A
KR20230084524A KR1020237014854A KR20237014854A KR20230084524A KR 20230084524 A KR20230084524 A KR 20230084524A KR 1020237014854 A KR1020237014854 A KR 1020237014854A KR 20237014854 A KR20237014854 A KR 20237014854A KR 20230084524 A KR20230084524 A KR 20230084524A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237014854A
Other languages
English (en)
Korean (ko)
Inventor
노암 레빈
3세 프랭크 제이 로워리
비맨 씨 파리아
스티븐 에이 로젠버그
라미 요셉
Original Assignee
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 filed Critical 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈
Publication of KR20230084524A publication Critical patent/KR20230084524A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A61K39/4611—
    • A61K39/4631—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
KR1020237014854A 2020-10-02 2021-10-01 G13d 돌연변이를 갖는 ras에 대한 hla 클래스 ii-제한된 dq t 세포 수용체 Pending KR20230084524A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063086674P 2020-10-02 2020-10-02
US63/086,674 2020-10-02
PCT/US2021/053060 WO2022072760A1 (en) 2020-10-02 2021-10-01 Hla class ii-restricted dq t cell receptors against ras with g13d mutation

Publications (1)

Publication Number Publication Date
KR20230084524A true KR20230084524A (ko) 2023-06-13

Family

ID=78676633

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237014854A Pending KR20230084524A (ko) 2020-10-02 2021-10-01 G13d 돌연변이를 갖는 ras에 대한 hla 클래스 ii-제한된 dq t 세포 수용체

Country Status (10)

Country Link
US (1) US12655195B2 (cg-RX-API-DMAC7.html)
EP (1) EP4222169A1 (cg-RX-API-DMAC7.html)
JP (1) JP7850143B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230084524A (cg-RX-API-DMAC7.html)
CN (1) CN116710111A (cg-RX-API-DMAC7.html)
AU (1) AU2021351710A1 (cg-RX-API-DMAC7.html)
CA (1) CA3194229A1 (cg-RX-API-DMAC7.html)
GB (1) GB2615010A (cg-RX-API-DMAC7.html)
TW (2) TW202540156A (cg-RX-API-DMAC7.html)
WO (1) WO2022072760A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024513651A (ja) 2021-02-26 2024-03-27 ニューヨーク ユニバーシティ 共有結合性ペプチドコンジュゲートに結合する抗体を含む組成物及び方法
WO2025056685A1 (en) * 2023-09-15 2025-03-20 Medigene Immunotherapies Gmbh T-CELL RECEPTOR AGAINST mKRAS7-16 G12V
WO2026024602A2 (en) * 2024-07-22 2026-01-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors against ras with g12d, g12v, g13d or q61r mutation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US20100286143A1 (en) * 2009-04-24 2010-11-11 Dora Dias-Santagata Methods and materials for genetic analysis of tumors
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
US20140134158A1 (en) * 2012-05-22 2014-05-15 Alberto Bardelli Kras mutations and resistance to anti-egfr treatment
SG10201913978RA (en) 2014-11-26 2020-03-30 The United States Of America As Represented By The Secretary Anti-mutated kras t cell receptors
JP2018518177A (ja) 2015-06-16 2018-07-12 タルゴバックス エーエスエー Rasタンパク質の突然変異フラグメント
SG10201913868XA (en) 2015-09-15 2020-03-30 The United States Of America As Represented By The Secretary T cell receptors recognizing hla-cw8 restricted mutated kras
US20170319638A1 (en) 2016-05-06 2017-11-09 Virttu Biologics Limited Treatment of cancer
GB201608052D0 (en) * 2016-05-09 2016-06-22 Univ Oslo Hf T-cell receptors which recognise frameshift mutants of TGF-beta RII
SG11201900654QA (en) 2016-08-02 2019-02-27 Us Health Anti-kras-g12d t cell receptors
KR20190062505A (ko) * 2016-10-03 2019-06-05 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
CN108395479B (zh) 2017-02-06 2021-07-16 高军 一种有关kras基因突变的t细胞受体
AU2018335274B2 (en) 2017-09-20 2025-02-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class II–restricted T cell receptors against mutated RAS
WO2019069125A1 (en) * 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
MX2020005765A (es) * 2017-12-04 2020-09-25 Us Health Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.
CN112585276A (zh) 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 产生表达重组受体的细胞的方法和相关组合物
SG11202012653XA (en) * 2018-06-19 2021-01-28 Biontech Us Inc Neoantigens and uses thereof
AU2019321608B2 (en) 2018-08-16 2024-07-25 Biontech Us Inc. T cell receptor constructs and uses thereof
US20220313803A1 (en) * 2019-01-07 2022-10-06 Brightpath Biotherapeutics Co., Ltd. Novel neoantigens and cancer immunotherapy using same
WO2020150364A1 (en) * 2019-01-15 2020-07-23 Altor Bioscience, Llc Human immunodeficiency virus-specific t cell receptors
CA3127673A1 (en) 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
WO2020191365A1 (en) * 2019-03-21 2020-09-24 Gigamune, Inc. Engineered cells expressing anti-viral t cell receptors and methods of use thereof
MX2021015946A (es) * 2019-06-18 2022-04-18 Regeneron Pharma Receptores de linfocitos t de mage-a4 y métodos de uso de estos.
DE102019121007A1 (de) * 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
CA3168015A1 (en) 2020-02-12 2021-08-19 Noam LEVIN Hla class i-restricted t cell receptors against ras with g12d mutation
AU2021227406A1 (en) 2020-02-24 2022-09-29 Oblique Therapeutics Ab Kras epitopes and antibodies
WO2021250511A1 (ko) * 2020-06-10 2021-12-16 주식회사 유틸렉스 Mr1에 결합하는 t-세포 수용체 및 이의 용도

Also Published As

Publication number Publication date
US20230365649A1 (en) 2023-11-16
CN116710111A (zh) 2023-09-05
GB2615010A (en) 2023-07-26
JP2023544592A (ja) 2023-10-24
TW202540156A (zh) 2025-10-16
AU2021351710A9 (en) 2025-03-20
EP4222169A1 (en) 2023-08-09
US12655195B2 (en) 2026-06-16
TW202229327A (zh) 2022-08-01
GB202305617D0 (en) 2023-05-31
JP7850143B2 (ja) 2026-04-22
CA3194229A1 (en) 2022-04-07
WO2022072760A1 (en) 2022-04-07
AU2021351710A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
TWI900528B (zh) 針對含有g12d突變之ras之hla第i類限制性t細胞受體
TWI902755B (zh) 針對含有g12v突變之ras之hla第i類限制性t細胞受體
TW201920251A (zh) 針對突變ras之hla第ii類限制性t細胞受體
US20230159614A1 (en) Hla class ii-restricted t cell receptors against ras with g12v mutation
JP7850143B2 (ja) G13d変異を有するrasに対するhlaクラスii拘束性dq t細胞受容体
KR20210118865A (ko) G12r 돌연변이를 갖는 ras에 대한 hla 클래스 ii-제한된 t 세포 수용체
KR20230043881A (ko) G12d 돌연변이를 갖는 ras에 대한 hla 클래스 ii-제한된 drb t 세포 수용체
TW202227477A (zh) 識別p53中r273c或y220c突變的t細胞受體
KR20230046294A (ko) G12v 돌연변이를 갖는 ras에 대한 hla 클래스 ii-제한된 drb t 세포 수용체
RU2849866C1 (ru) T-клеточные рецепторы, рестриктированные по hla класса i, против ras с мутацией g12d
WO2022225836A1 (en) Hla class i-restricted t cell receptors against ras with q61k mutation

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000